Skip to main content

01.12.2018 | Letter | Ausgabe 1/2018 Open Access

Critical Care 1/2018

Adjuvant vitamin C in cardiac arrest patients undergoing renal replacement therapy: an appeal for a higher high-dose

Critical Care > Ausgabe 1/2018
Patrick M. Honore, David De Bels, Thierry Preseau, Sebastien Redant, Rachid Attou, Herbert D. Spapen
Continuous renal replacement therapy
Renal replacement therapy
Vit C
Vitamin C
We read with interest the excellent review of Spoelstra-de Man et al. which focused on the potential benefit of adjuvant vitamin C (vit C) therapy in ischemia-reperfusion injury [ 1]. Following an exhaustive in-depth analysis of the impressive experimental, clinical, and safety record of vit C, the authors plead for a randomized controlled clinical trial assessing the effect of early, high-dose (i.e., at least 3 g/day), intravenous vit C administration in post-cardiac arrest patients.
About half of the patients may develop acute kidney injury stage ≥ 1 within 2 days after cardiac arrest and 20 to 60% will require renal replacement therapy (RRT) [ 2]. Vit C has a molecular weight of 176 Dalton and is thus exposed to significant clearance during RRT. Intermittent hemodialysis as well as continuous RRT (CRRT) are indeed associated with a 50% reduction of plasma ascorbate and vit C levels [ 35]. Diffusion and convection account for two-thirds and one-third, respectively, of the vit C loss [ 3]. A 3 g daily vit C dose, therefore, is by no means guaranteed to cover the acute need in post-cardiac arrest patients initiated on (C)RRT. Vasopressor-dependent subjects in particular may benefit from increased dosing because vit C has been shown to support endogenous vasoactive catecholamine synthesis. Awaiting solid pharmacological data, we propose to supplement post-cardiac arrest patients not treated with CRRT with 6 g vit C daily. If CRRT is running, the dose should be increased to 12 g. We fully agree with Spoelstra-de Man et al. to administer vit C as early as possible (i.e., before intensive care admission) and to continue treatment for a short period of time.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Critical Care 1/2018 Zur Ausgabe

Neu im Fachgebiet AINS

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update AINS und bleiben Sie gut informiert – ganz bequem per eMail.